- Home
- QLGN vs SLXN Comparison
QLGN vs SLXN Comparison
Compare QLGN & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- SLXN
- Stock Information
- Founded
- QLGN 1996
- SLXN 2008
- Country
- QLGN United States
- SLXN Israel
- Employees
- QLGN 4
- SLXN N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- SLXN
- Sector
- QLGN Health Care
- SLXN
- Exchange
- QLGN Nasdaq
- SLXN NYSE
- Market Cap
- QLGN 2.7M
- SLXN 3.0M
- IPO Year
- QLGN N/A
- SLXN N/A
- Fundamental
- Price
- QLGN $3.60
- SLXN $0.21
- Analyst Decision
- QLGN
- SLXN Strong Buy
- Analyst Count
- QLGN 0
- SLXN 1
- Target Price
- QLGN N/A
- SLXN $1.00
- AVG Volume (30 Days)
- QLGN 226.0K
- SLXN 1.5M
- Earning Date
- QLGN 11-29-2024
- SLXN 11-14-2024
- Dividend Yield
- QLGN N/A
- SLXN N/A
- EPS Growth
- QLGN N/A
- SLXN N/A
- EPS
- QLGN N/A
- SLXN N/A
- Revenue
- QLGN N/A
- SLXN N/A
- Revenue This Year
- QLGN N/A
- SLXN N/A
- Revenue Next Year
- QLGN N/A
- SLXN N/A
- P/E Ratio
- QLGN N/A
- SLXN N/A
- Revenue Growth
- QLGN N/A
- SLXN N/A
- 52 Week Low
- QLGN $3.55
- SLXN $0.21
- 52 Week High
- QLGN $39.15
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- QLGN 25.42
- SLXN N/A
- Support Level
- QLGN $3.71
- SLXN N/A
- Resistance Level
- QLGN $4.56
- SLXN N/A
- Average True Range (ATR)
- QLGN 0.65
- SLXN 0.00
- MACD
- QLGN -0.06
- SLXN 0.00
- Stochastic Oscillator
- QLGN 2.08
- SLXN 0.00
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.